Navigation Links
Treatment for alcohol dependence might work best in certain populations, research suggests
Date:3/16/2011

This release is available in French.

MONTREAL March 16, 2011 - Results from a new study suggest that one of the most prescribed medications for alcohol dependence may be more effective in some people. Preliminary results show that naltrexone (Revia), one of the only medications approved for treating people with alcohol abuse problems, may only be effective in women and those with a specific genetic variation. The new study, conducted by researchers from the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University, will be published in the journal Alcoholism: Clinical and Experimental Research.

Previous work suggested that naltrexone only helped some people with alcohol problems, but the reason for that was unclear. "Our results suggest that we might now be able to predict beforehand who will benefit most," says Dr. Marco Leyton, lead investigator of the study and a researcher in the Mental Illnesses and Addiction axis at the RI MUHC. "We were quite excited to find that our results supported that naltrexone was specifically effective in women and in people who carried a gene related to the brain's natural morphine system called the mu opioid receptor gene (OPRM1)."

In this study, researchers followed a small group of "social drinkers" in an effort to validate some very preliminary hints that the efficacy of the treatment might be related to gender and a particular gene that may be inherited. These findings could help ensure that we give the right medication to the right people," says Dr. Leyton, who is also and associate professor in the Department of Psychiatry at McGill.

Researchers and clinicians might be able to determine who might best respond to this treatment, before it was administrated. "If a particular individual with alcohol dependence had these features, we could then say with much more confidence that this is going to help you. For other individuals who don't have those features, we'll be able to say, don't waste your time with this medication, we should try something else for you", explains Dr. Leyton. "These findings have the potential to improve the quality of treatment for alcohol dependent patients and they could ultimately lead to a form of personalized medicine."

Alcohol stimulates the release of the brain's natural opioids, which conveys a feeling of euphoria in individuals when drinking alcohol. There seem to be individual differences in the magnitude of that effect as well as in the sensitivity of the receptors to those natural opioids. "In other words, an opioid receptor blocker, such as naltrexone, might be an effective treatment for people with alcohol problems by decreasing the euphoria of drinking," explains Ms. Elaine Setiawan, first author of the study and PhD candidate in McGill's Integrated Program in Neuroscience.

At this point there is no particular reason to think that these findings couldn't be applied to other groups, such as those with a family history of alcoholism or those with high alcohol craving. But as Dr. Leyton suggests, "further research needs to be done in all sorts of populations and with a much larger sample to better understand the connection between the brain's opioid system, genetics and different responses to naltrexone."


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-843-1696
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Herbal Derivative Wins Praise as Malaria Treatment
2. Chasing the pot of gold: WSU researchers study gambling subtypes and treatment outcomes
3. Unusual treatment of colonic perforation
4. Potential new treatment to reduce the burden of atherosclerosis in acute coronary syndrome patients
5. New insights into cancer treatment
6. Research shows rapid adoption of newer, more expensive prostate cancer treatments
7. UTHealth study: Stem cells may provide treatment for brain injuries
8. University of Michigan Cardiovascular Center studies new treatment for high-risk aortic patients
9. ADAM-12 gene could hold key to cancer, arthritis and cardiac treatments
10. Research study explores gene therapy treatment to reduce symptoms of Parkinsons disease
11. The safety of daily magnesium oxide treatment for children with chronic constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: